Similarly, a tri-specific antibody targeting HER2, CD3 and CD28 has caused regression of breast cancers in a humanized mouse model through CD4-dependent inhibition of tumor cell cycle progression (63–65). This evidence concerns the gene ERBB2 and neoplasm.